188 related articles for article (PubMed ID: 11995778)
1. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women.
Rasgon NL; Altshuler LL; Fairbanks LA; Dunkin JJ; Davtyan C; Elman S; Rapkin AJ
J Clin Psychiatry; 2002; 63 Suppl 7():45-8. PubMed ID: 11995778
[TBL] [Abstract][Full Text] [Related]
2. Fluoxetine efficacy in menopausal women with and without estrogen replacement.
Amsterdam J; Garcia-España F; Fawcett J; Quitkin F; Reimherr F; Rosenbaum J; Beasley C
J Affect Disord; 1999 Sep; 55(1):11-7. PubMed ID: 10512601
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms.
Soares CN; Poitras JR; Prouty J; Alexander AB; Shifren JL; Cohen LS
J Clin Psychiatry; 2003 Apr; 64(4):473-9. PubMed ID: 12716252
[TBL] [Abstract][Full Text] [Related]
4. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report.
Cohen LS; Soares CN; Poitras JR; Prouty J; Alexander AB; Shifren JL
Am J Psychiatry; 2003 Aug; 160(8):1519-22. PubMed ID: 12900318
[TBL] [Abstract][Full Text] [Related]
5. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group.
Schneider LS; Small GW; Hamilton SH; Bystritsky A; Nemeroff CB; Meyers BS
Am J Geriatr Psychiatry; 1997; 5(2):97-106. PubMed ID: 9106373
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial.
Soares CN; Almeida OP; Joffe H; Cohen LS
Arch Gen Psychiatry; 2001 Jun; 58(6):529-34. PubMed ID: 11386980
[TBL] [Abstract][Full Text] [Related]
7. Does estrogen enhance the antidepressant effects of fluoxetine?
Westlund Tam L; Parry BL
J Affect Disord; 2003 Oct; 77(1):87-92. PubMed ID: 14550939
[TBL] [Abstract][Full Text] [Related]
8. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder.
Iosifescu DV; Nierenberg AA; Mischoulon D; Perlis RH; Papakostas GI; Ryan JL; Alpert JE; Fava M
J Clin Psychiatry; 2005 Aug; 66(8):1038-42. PubMed ID: 16086620
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
Silverstone PH; Salinas E
J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
[TBL] [Abstract][Full Text] [Related]
10. Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression.
Simpson GM; El Sheshai A; Rady A; Kingsbury SJ; Fayek M
J Clin Psychiatry; 2003 Aug; 64(8):959-65. PubMed ID: 12927014
[TBL] [Abstract][Full Text] [Related]
11. Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination?
Levitt AJ; Joffe RT; Kamil R; McIntyre R
J Clin Psychiatry; 1999 Sep; 60(9):613-6. PubMed ID: 10520980
[TBL] [Abstract][Full Text] [Related]
12. Lack of association of acute phase response proteins with hormone levels and antidepressant medication in perimenopausal depression.
Karaoulanis SE; Rizouli KA; Rizoulis AA; Angelopoulos NV
BMC Psychiatry; 2014 Jun; 14():164. PubMed ID: 24894416
[TBL] [Abstract][Full Text] [Related]
13. Residual symptoms in depressed patients who respond acutely to fluoxetine.
Nierenberg AA; Keefe BR; Leslie VC; Alpert JE; Pava JA; Worthington JJ; Rosenbaum JF; Fava M
J Clin Psychiatry; 1999 Apr; 60(4):221-5. PubMed ID: 10221281
[TBL] [Abstract][Full Text] [Related]
14. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression.
Ladd CO; Newport DJ; Ragan KA; Loughhead A; Stowe ZN
Depress Anxiety; 2005; 22(2):94-7. PubMed ID: 16094663
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis.
Zajecka JM; Jeffries H; Fawcett J
J Clin Psychiatry; 1995 Aug; 56(8):338-43. PubMed ID: 7635848
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.
Schmidt ME; Fava M; Robinson JM; Judge R
J Clin Psychiatry; 2000 Nov; 61(11):851-7. PubMed ID: 11105738
[TBL] [Abstract][Full Text] [Related]
17. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
Entsuah AR; Huang H; Thase ME
J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046
[TBL] [Abstract][Full Text] [Related]
18. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
Wheatley DP; van Moffaert M; Timmerman L; Kremer CM
J Clin Psychiatry; 1998 Jun; 59(6):306-12. PubMed ID: 9671343
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
20. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
